The DOI matches its Crossref record.
Let’s talk about lipid nanoparticles
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, bioPROTACs would most likely be delivered as mRNA or DNA constructs via a viral vector gene delivery system204–206 or in a nanoparticle207–209.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [209]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorted by citations
Items 101–119 of 119
Role of Nanomedicine in Overcoming Antimicrobial Resistance: Challenges and Opportunities
Mukherjee, R., Chang, C.-M., Pandey, R. P., et al. (2024) · Springer eBooks · doi:10.1007/978-981-97-2023-1_2 · Cited by 2
Recent advances in nanoparticle-based approaches for the treatment of multiple myeloma
Oprea, M., Voicu, Ș. I., & Ionita, M. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102849 · Cited by 3
Immunogenicity of Recombinant Lipid-Based Nanoparticle Vaccines: Danger Signal vs. Helping Hand
Temchura, V., Wagner, J. T., & Damm, D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010024 · Cited by 3
Combating HIV Latency: A Review of Innovative Interventions and Nanotechnology-Based Formulations
Dubey, D., Fernandes, T., & Singh, P. (2025) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2025054733 · Cited by 1
Next-Generation Nanoparticle-Enabled mRNA Vaccines in the Treatment of COVID-19
Kole, E. B., Jadhav, K., Singh, R., Verma, R. K., Chatterjee, A., & Naik, J. (2025) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2025053265 · Cited by 1
Garbujo, S., Baioni, C., Banfi, A., Bolis, L., Bonvini, G., Favero, E. D., Gagni, P., Gori, A., Barbieri, L., Giustra, M., et al. (2026) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2026.139972 · Cited by 1
Ellison, G. M. (2022) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2022.05 · Cited by 1
Therapeutic targeting non-coding RNAs
Ray, R. M., Lazăr, A. D., Balahura, L.-R., Dobranici, A., Costache, M., & Dinescu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90406-3.00006-3 · Cited by 1
Nanotherapeutics for ocular posterior segment diseases therapy: Towards its advances and challenges
Li, M., Cai, S., Li, H., Cheng, Y., Ye, J., Ke, L., Han, Y., Su, M., Liu, G., & Chu, C. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111392 · Cited by 1
Therapeutic Modalities for Coronavirus SARS-CoV-2 (COVID-19)
(2022) · Advances in Hematology and Oncology Research · doi:10.33140/ahor.05.01.06
Genetically-encoded degraders as versatile modulators of intracellular therapeutic targets
Dai, C., Wang, J., Tu, L., Pan, Z., Yang, J., Zhou, S. Y., Luo, Q., Zhu, L., & Ye, Y. (2023) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2023.100458 · Cited by 1
Clark, D. P., Pazdernik, N. J., McGehee, M. R., et al. (2025) · Biotechnology · doi:10.1016/b978-0-443-18484-0.00006-7
Design and evaluation of therapeutic particles modulating autophagy
Zagkou, S. (2021) · theses.fr (ABES) · doi:10.70675/945352cczdaf3z45fczb8dezdc79d3ca5100
Hadji, H. (2021) · theses.fr (ABES) · doi:10.70675/84bd1d3bz2f32z4363z88d8z7ace5e2d9a79
Novel Nanotechnological Approaches for Glioblastoma Targeting
Rinaldi, A. (2024) · theses.fr (ABES) · doi:10.70675/f2906991zf1b3z4908z89b3z3540c81fe044
Ahalwat, S., Yadav, S., Chauhan, M., Rawat, A., & Dahiya, R. (2026) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2026.101645 · Cited by 1
Overview of the Fundamentals of the Synthesis of Nanoparticles and Characterization Techniques
Sen, S., Das, C., & Biswas, G. (2026) · Springer eBooks · doi:10.1007/978-3-032-24518-2_2
New paradigm in relation to cytotoxicity and genotoxicity of nanoparticles and nanomaterials
Zhang, P., & Niemelä, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-36328-3.00013-9
Parameswaran, D., Suriya Prakaash, K. K., & Narayanasamy, D. (2026) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2026.2703793
“…the standard FDA and eMA approval timeline typically spans 6–9 months, with delays often due to technical challenges and research complexities [69]. to meet regulatory quality standards for liposomes, comprehensive characterization and toxicological studies are necessary, followed by specific…”
Metadata
- Venue
- Nature Reviews Materials
- Published
- 2021-02-09
- Volume
- 6
- Issue
- 2
- Pages
- 99-99
- ISSN
- 2058-8437 (ISSN-L)
- OpenAlex
- W4253670085
- Cited by
- 119
- References
- 0
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 26 · 2023: 21 · 2022: 26 · 2021: 22
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature Reviews Materials (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- lipid nanoparticles, mRNA vaccines, COVID-19 pandemic, small molecule delivery, nanomedicine, vaccine delivery vehicles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
